|Day Low/High||31.09 / 31.92|
|52 Wk Low/High||28.25 / 37.39|
The Dow Jones Industrial Average roared to new records on Friday and ended with weekly gains for the fifth time in a row.
Stocks are on track to close at fresh records on Friday as the health care sector makes a comeback after a bruising week.
It's the most random day of the week, with stocks all over the map.
Stocks move higher on Friday, trading at records, as the health care sector makes a comeback after a bruising week.
After four weeks of steady decline Pfizer returns to a very solid support zone.
Wall Street sets new records on Thursday as a broad rally in equities resumes.
Wall Street is on track to smash closing records on Thursday as a broad rally among stocks resumes.
Stocks turn higher but only slightly as the Dow Jones Industrial Average and S&P 500 attempt to set new records..
Pfizer could have anything happen to it today, particularly as President-elect Donald Trump could send out a tweet about drug pricing, TheStreet's Jim Cramer said.
The U.K. regulator takes exception to the sale of Epanutin to Flynn Pharma, which drove the price up by 2,600%.
U.S. stock futures rise following another record close for the Dow Jones Industrial Average; Pfizer is fined $107 million for hiking the price of an epilepsy drug.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and CEO, at the Guggenheim 4 th Annual Boston Healthcare Conference on Tuesday, December 13, 2016 at...
Today, Pfizer Inc. and its partner Avillion LLP announced results from the Phase 3 BFORE ( B osutinib trial in F irst line chr O nic myelogenous leukemia t RE atment) trial demonstrating superiority of...
Spark believes temporary treatment with steroids can arrest the immune response before it causes factor IX levels to fall to a point where bleeding risk becomes a problem.
Today, Pfizer Inc. (NYSE:PFE) announced new data from a randomized Phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose cytarabine (LDAC) significantly...
Chevron and Pfizer may not just be big yielders in 2017, but big winners too, says Morgan Stanley's Dan Skelly.
Collaboration combines IBM Watson's cognitive computing capabilities with Pfizer's scientific knowledge to help scientists generate meaningful insights
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Citi 2016 Global Healthcare Conference on...
Pfizer Inc. (NYSE:PFE) announced today positive top-line results of a study that evaluated the use of LYRICA® (pregabalin) Capsules CV and Oral Solution CV as adjunctive therapy for pediatric epilepsy patients four to...
New Interoperability Is Designed to Streamline Clinical Workflow
In a record year for acquisitions, 18 companies from across the spectrum were singled out by M&A professionals for doing deals that got results.
Each dividend stock scores well for safety and has a historically high dividend yield.
Pfizer Inc. (NYSE:PFE) today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin® (trastuzumab), met its primary endpoint.
A Brazilian plane crash near Medellín on Monday included 21 journalists, among the largest number of media personnel to die in any one incident.
Stocks climbed as evidence of an economy on the mend overshadowed a slump in crude oil prices.
Wall Street ended just shy of records on Tuesday as a collapse in crude oil prices limited upward momentum.
Shares of Pfizer were slightly higher on Tuesday as Barclays upgraded its rating to Overweight from Equal Weight
Stocks climb on Tuesday as evidence of an economy on the mend overshadows a slump in crude oil prices.